Cargando…

Prediction of Efficacy of Vabicaserin, a 5-HT(2C) Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model

A quantitative systems pharmacology model that combines in vitro/preclinical neurophysiology data, human imaging data, and patient disease information was used to blindly predict steady-state clinical efficacy of vabicaserin, a 5-HT(2C) full agonist, in monotherapy and, subsequently, to assess adjun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, J, Ogden, A, Comery, T A, Spiros, A, Roberts, P, Geerts, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011163/ https://www.ncbi.nlm.nih.gov/pubmed/24759548 http://dx.doi.org/10.1038/psp.2014.7

Ejemplares similares

Imaging Evaluation of 5HT(2C) Agonists, [(11)C]WAY-163909 and [(11)C]Vabicaserin, Formed by Pictet–Spengler Cyclization
por: Neelamegam, Ramesh, et al.
Publicado: (2014)

A Quantitative System Pharmacology Computer Model for Cognitive Deficits in Schizophrenia
por: Geerts, H, et al.
Publicado: (2013)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

5-HT1A agonists, 5-HT3 antagonists and benzodiazepines : their comparative behavioural pharmacology /
Publicado: (1991)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

A single channel mutation alters agonist efficacy at 5-HT(3)A and 5-HT(3)AB receptors
por: Thompson, A J, et al.
Publicado: (2013)

Bulking up the hippocampus in schizophrenia: a role for 5-HT(1A) agonists?
por: Frangou, Sophia
Publicado: (2016)

Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
por: Yempala, Thirumal, et al.
Publicado: (2020)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Altered 5-HT(2C )receptor agonist-induced responses and 5-HT(2C )receptor RNA editing in the amygdala of serotonin transporter knockout mice
por: Moya, Pablo R, et al.
Publicado: (2011)

The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties
por: Beattie, David T., et al.
Publicado: (2011)

Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response
por: Geerts, Hugo, et al.
Publicado: (2012)

Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT(2C) Agonists
por: Kim, Juhyeon, et al.
Publicado: (2019)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Characterization of the 5-HT(2C) receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity
por: Higgins, Guy A, et al.
Publicado: (2015)

Editorial: Contemporary Perspective on 5-HT(2C) Receptor Function and Its Pharmacological Targeting
por: De Deurwaerdère, Philippe, et al.
Publicado: (2020)

Effect of Selective 5-HT6R Agonist on Expression of 5-HT Receptor and Neurotransmitter in Vascular Dementia Rats
por: Yu, Haining, et al.
Publicado: (2017)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Anti-PTSD Effects of Hypidone Hydrochloride (YL-0919): A Novel Combined Selective 5-HT Reuptake Inhibitor/5-HT(1A) Receptor Partial Agonist/5-HT(6) Receptor Full Agonist
por: Liu, Wen-Gang, et al.
Publicado: (2021)

Quantitative proteomic analysis reveals the effects of mu opioid agonists on HT22 cells
por: Zhang, Xutong, et al.
Publicado: (2023)

Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT(2A )or 5-HT(2C )receptors
por: Seitz, Patricia K, et al.
Publicado: (2012)

Effects of (−)‐MBP, a novel 5‐HT(2C) agonist and 5‐HT(2A/2B) antagonist/inverse agonist on brain activity: A phMRI study on awake mice
por: Sathe, Preeti K., et al.
Publicado: (2023)

Opposite alterations of 5HT(2A) receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile
por: Diez-Alarcia, Rebeca, et al.
Publicado: (2021)

Agonists and antagonists induce different palonosetron dissociation rates in 5-HT(3)A and 5-HT(3)AB receptors()
por: Lummis, Sarah C.R., et al.
Publicado: (2013)

Translating the promise of 5HT(4) receptor agonists for the treatment of depression
por: Murphy, Susannah E, et al.
Publicado: (2021)

5-HT1A and 5-HT2A Signaling, Desensitization, and Downregulation: Serotonergic Dysfunction and Abnormal Receptor Density in Schizophrenia and the Prodrome
por: Kim, Sun A
Publicado: (2021)

The 5-HT(2C) receptor agonist, lorcaserin, and the 5-HT(6) receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour
por: Higgs, Suzanne, et al.
Publicado: (2015)

Investigating interactions between phentermine, dexfenfluramine, and 5-HT(2C) agonists, on food intake in the rat
por: Grottick, Andrew J., et al.
Publicado: (2014)

Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT(2C) Receptor
por: Veeramachaneni, Ganesh Kumar, et al.
Publicado: (2019)

5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
por: Przegaliński, Edmund, et al.
Publicado: (2023)

Effect of the 5-HT(2C) Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study
por: Whitestone, Sara, et al.
Publicado: (2019)

Radiosynthesis and preclinical evaluation of [(11)C]prucalopride as a potential agonist PET ligand for the 5-HT(4) receptor
por: Buiter, Hans JC, et al.
Publicado: (2013)

Biophysical validation of serotonin 5-HT(2A) and 5-HT(2C) receptor interaction
por: Felsing, Daniel E., et al.
Publicado: (2018)

Pharmacological Characterization of 5-HT(1A) Autoreceptor-Coupled GIRK Channels in Rat Dorsal Raphe 5-HT Neurons
por: Montalbano, Alberto, et al.
Publicado: (2015)

SB 206553, a putative 5-HT(2C) inverse agonist, attenuates methamphetamine-seeking in rats
por: Graves, Steven M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rhh8jfc2gvd338hr68nsg7rkji